September 25, 2017


Via EDGAR Correspondence

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549


Ms. Irene Paik



Re: Ohr Pharmaceutical, Inc.

Registration Statement on Form S-3

Filed September 15, 2017
File No. 333-220487


Dear Ms. Paik:


Pursuant to Rule 461 of the Securities Act of 1933, as amended, the undersigned registrant under the above-referenced registration statement hereby requests acceleration of the effective date of the registration statement to September 27, 2017, at 4:00 p.m., New York time, or as soon as practicable thereafter. Please notify our outside counsel, Joseph Walsh, Esq., by phone at (212) 704-6030, by fax at (212) 704-5919, or by email at of the date and time that the registration statement has been declared effective.



  Very truly yours,
  Ohr Pharmaceutical, Inc.
  By: /s/ Sam Backenroth  
    Name:  Sam Backenroth
    Title:    Chief Financial Officer



cc: Dr. Jason Slakter, Chief Executive Officer, Ohr Pharmaceutical, Inc.
  Aurora Cassirer, Esq. Troutman Sanders, LLP  
  Joseph Walsh, Esq., Troutman Sanders, LLP